Results 11 to 20 of about 259,058 (180)

HbA1c Variability and Cardiovascular Events in Patients with Prostate Cancer Receiving Androgen Deprivation Therapy [PDF]

open access: yes, 2022
BACKGROUND: Androgen deprivation therapy (ADT) worsens glycaemic control and cardiovascular outcomes. The prognostic value of visit-to-visit HbA1c variability (VVHV) has been unexplored in prostate cancer (PCa) patients receiving ADT.
Tse, Gary   +9 more
core   +3 more sources

Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer [PDF]

open access: yes, 2001
Objective To examine the role of androgen receptor (AR) gene amplification and aneusomy of the X chromosome in the development of antiandrogen-resistant prostate cancer.
Watters, A.D.   +5 more
core   +1 more source

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor [PDF]

open access: yes, 2005
Prostate cancer is the second most common male malignancy in the western world an increasing incidence in an ageing population. Treatment of advanced prostate cancer relies on androgen deprivation.
Edwards, J., Bartlett, J.M.S.
core   +1 more source

Bad expression influences time to androgen escape in prostate cancer [PDF]

open access: yes, 2007
<b>OBJECTIVE</b>: To assess the role of selected downstream Bcl-2 family members (Bad, Bax, Bcl-2 and Bcl-xL) in the development of androgen-independent prostate cancer (AIPC), as androgen-deprivation therapy is the treatment of choice in ...
Teo, K.   +4 more
core   +1 more source

What Is Your Choice for Androgen Deprivation Therapy in Metastatic Prostate Carcinoma: Surgical or Medical?

open access: yes, 2022
OBJECTIVE: : At the time of diagnosis, approximately 16.5% of prostate cancer patients are metastatic. The main framework of metastatic prostate cancer treatment is androgen deprivation therapy, which is performed surgically or medically. The aim of this
Kisa, Erdem   +22 more
core   +1 more source

Long-term cardiovascular burden in prostate cancer patients receiving androgen deprivation therapy [PDF]

open access: yes, 2022
Androgen deprivation therapy (ADT), which pharmacologically or surgically suppresses androgen activity, is a key treatment for prostate cancer (PCa).1 However, it is associated with increased cardiovascular risks, including elevated risks of ...
Tse, G.
core  

The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways [PDF]

open access: yes, 2005
Prostate cancer is the second leading cause of cancer related deaths in men from the western world. Treatment of prostate cancer has relied on androgen deprivation therapy for the past 50 years.
J Edwards   +3 more
core   +1 more source

A 3D in vitro model reflecting the androgen deprivation state in prostate cancer bone metastasis [PDF]

open access: yes, 2015
In castrate-resistant prostate\ud cancer (CRPC), the prevailing organ for\ud metastasis is bone, where the survival of\ud cancer cells is regulated by the permissive\ud metastatic niche offered by the bone marrow.\ud The tumour microenvironment and\ud ...
Loessner, Daniela   +3 more
core   +3 more sources

From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells [PDF]

open access: yes, 2013
Elucidating the role of androgen deprivation in the transition from androgen-dependence to independence may enable the development of more specific therapeutic strategies against prostate cancer. Our previous in vitro model was employed to further assess
Mendes, Desiree E   +2 more
core   +1 more source

Denosumab in men receiving androgen-deprivation therapy for prostate cancer [PDF]

open access: yes, 2009
Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. We investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of ...
Szwedowski, M.   +25 more
core   +1 more source

Home - About - Disclaimer - Privacy